ADVERTISEMENT

COVID vaccines effective vs. Omicron surge --- Nograles

Published Jan 12, 2022 02:14 pm

Cabinet Secretary and Acting Presidential Spokesperson Karlo Nograles has underscored the effectiveness of coronavirus disease (COVID-19) vaccines amid the current surge in new cases of the dreaded illness.

(Hakan Nural/ Unsplash)

“Please allow us to reiterate that the protection provided by vaccines comes not just in the form of reducing the likelihood of infection–it also comes in the form of reducing the risk of developing severe COVID symptoms," Nograles said during a virtual press conference Tuesday, Jan. 11.

"Pag bakunado po kayo, malaki po ang chance na kung mahawa man kayo ng COVID, magiging mild lang po ang symptoms ninyo (If you are vaccinated, there's a big chance that you'll only contract mild symptoms of COVID),” emphasized Nograles, who also serves as spokesperson of the Inter-Agency Task Force for the Management of Emerging Infectious Diseases (IATF).

The Philippines is currently grappling with a ferocious new surge in COVID-19 cases that's supposedly being fueled by the Omicron variant.

“Kahit matindi makahawa ang Omicron, hindi po tayo helpless (We are not helpless even if Omicron is very contagious); we can do something about it," he said.

"Magpabakuna na po tayo, anumang brand ito, para maging ligtas, para sa karagdagang proteksyon natin, ng ating mga mahal sa buhay at ng ating komunidad (In order to be safe and to give ourselves, our loved ones and ouu community additional protection, let's get ourselves vaccinated--the vaccine brand doesn't matter)," stressed the Palace official.

The country is coming off a record day in terms of new COVID-19 infections last Jan. 10, when it recorded a whopping 33,169 cases.

According to Nograles, the vast majority or 97.1 percent of the 33,169 cases tallied exhibited mild symptoms or are asymptomatic.

He said that while there are more COVID-positive cases being recorded now compared to the previous surge last September, there are less people developing severe and critical forms of the disease.

“Dahil ito sa malawakang pagbabakuna (This is due to widespread vaccination)," he pointed out.

"Hindi kami magsasawa sa pagpa-paalala: Ang mga bakuna natin laban sa COVID-19 ay may Emergency Use Authorization mula sa Food and Drug Administration. Lahat ng ito ay ligtas at epektibo. Lahat–anuman ang brand–ay nagbibigay ng proteksyon laban sa severe at critical cases ng coronavirus (We will not stop in reminding you: Our vaccines against COVID-19 have Emergency Use Authorization from the Food and Drug Administration. All of these are safe and effective. Vaccines of all brands give protection against severe and critical cases of coronavirus)," Nograles said.

Related Tags

brands effective Karlo Nograles vaccines covid-19 Omicron effectiveness record-high protection
ADVERTISEMENT
.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1561_widget.title }}

.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1562_widget.title }}

.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1563_widget.title }}

{{ articles_filter_1564_widget.title }}

.mb-article-details { position: relative; } .mb-article-details .article-body-preview, .mb-article-details .article-body-summary{ font-size: 17px; line-height: 30px; font-family: "Libre Caslon Text", serif; color: #000; } .mb-article-details .article-body-preview iframe , .mb-article-details .article-body-summary iframe{ width: 100%; margin: auto; } .read-more-background { background: linear-gradient(180deg, color(display-p3 1.000 1.000 1.000 / 0) 13.75%, color(display-p3 1.000 1.000 1.000 / 0.8) 30.79%, color(display-p3 1.000 1.000 1.000) 72.5%); position: absolute; height: 200px; width: 100%; bottom: 0; display: flex; justify-content: center; align-items: center; padding: 0; } .read-more-background a{ color: #000; } .read-more-btn { padding: 17px 45px; font-family: Inter; font-weight: 700; font-size: 18px; line-height: 16px; text-align: center; vertical-align: middle; border: 1px solid black; background-color: white; } .hidden { display: none; }
function initializeAllSwipers() { // Get all hidden inputs with cms_article_id document.querySelectorAll('[id^="cms_article_id_"]').forEach(function (input) { const cmsArticleId = input.value; const articleSelector = '#article-' + cmsArticleId + ' .body_images'; const swiperElement = document.querySelector(articleSelector); if (swiperElement && !swiperElement.classList.contains('swiper-initialized')) { new Swiper(articleSelector, { loop: true, pagination: false, navigation: { nextEl: '#article-' + cmsArticleId + ' .swiper-button-next', prevEl: '#article-' + cmsArticleId + ' .swiper-button-prev', }, }); } }); } setTimeout(initializeAllSwipers, 3000); const intersectionObserver = new IntersectionObserver( (entries) => { entries.forEach((entry) => { if (entry.isIntersecting) { const newUrl = entry.target.getAttribute("data-url"); if (newUrl) { history.pushState(null, null, newUrl); let article = entry.target; // Extract metadata const author = article.querySelector('.author-section').textContent.replace('By', '').trim(); const section = article.querySelector('.section-info ').textContent.replace(' ', ' '); const title = article.querySelector('.article-title h1').textContent; // Parse URL for Chartbeat path format const parsedUrl = new URL(newUrl, window.location.origin); const cleanUrl = parsedUrl.host + parsedUrl.pathname; // Update Chartbeat configuration if (typeof window._sf_async_config !== 'undefined') { window._sf_async_config.path = cleanUrl; window._sf_async_config.sections = section; window._sf_async_config.authors = author; } // Track virtual page view with Chartbeat if (typeof pSUPERFLY !== 'undefined' && typeof pSUPERFLY.virtualPage === 'function') { try { pSUPERFLY.virtualPage({ path: cleanUrl, title: title, sections: section, authors: author }); } catch (error) { console.error('ping error', error); } } // Optional: Update document title if (title && title !== document.title) { document.title = title; } } } }); }, { threshold: 0.1 } ); function showArticleBody(button) { const article = button.closest("article"); const summary = article.querySelector(".article-body-summary"); const body = article.querySelector(".article-body-preview"); const readMoreSection = article.querySelector(".read-more-background"); // Hide summary and read-more section summary.style.display = "none"; readMoreSection.style.display = "none"; // Show the full article body body.classList.remove("hidden"); } document.addEventListener("DOMContentLoaded", () => { let loadCount = 0; // Track how many times articles are loaded const offset = [1, 2, 3, 4, 5, 6, 7, 8, 9, 10]; // Offset values const currentUrl = window.location.pathname.substring(1); let isLoading = false; // Prevent multiple calls if (!currentUrl) { console.log("Current URL is invalid."); return; } const sentinel = document.getElementById("load-more-sentinel"); if (!sentinel) { console.log("Sentinel element not found."); return; } function isSentinelVisible() { const rect = sentinel.getBoundingClientRect(); return ( rect.top < window.innerHeight && rect.bottom >= 0 ); } function onScroll() { if (isLoading) return; if (isSentinelVisible()) { if (loadCount >= offset.length) { console.log("Maximum load attempts reached."); window.removeEventListener("scroll", onScroll); return; } isLoading = true; const currentOffset = offset[loadCount]; window.loadMoreItems().then(() => { let article = document.querySelector('#widget_1690 > div:nth-last-of-type(2) article'); intersectionObserver.observe(article) loadCount++; }).catch(error => { console.error("Error loading more items:", error); }).finally(() => { isLoading = false; }); } } window.addEventListener("scroll", onScroll); });

Sign up by email to receive news.